NEW YORK, Jan. 3, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on GRFS, ADXS, NKTR, and ONCE which can be accessed for free by signing up to www.wallstequities.com/registration. On Tuesday, January 02, 2018, US markets saw broad based gains with eight
On Tuesday, shares in Barcelona, Spain headquartered Grifols S.A. recorded a trading volume of 970,314 shares, which was above their three months average volume of 530.32 thousand shares. The stock ended the session 2.09% higher at $23.40. The Company's shares have gained 45.61% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 4.28% and 10.77%, respectively. Moreover, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, have a Relative Strength Index (RSI) of 66.87. Get the full research report on GRFS for free by clicking below at:
Princeton, New Jersey-based Advaxis Inc.'s stock closed the day 9.15% higher at $3.10 with a total trading volume of 1.24 million shares, which was above their three months average volume of 773.62 thousand shares. The Company's shares have advanced 9.15% since the start of this year. The stock is trading below its 50-day moving average by 1.01%. Additionally, shares of Advaxis, which focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the US, have an RSI of 52.30. Free research on ADXS can be accessed at:
Shares in San Francisco, California headquartered Nektar Therapeutics recorded a trading volume of 2.00 million shares. The stock ended yesterday's trading session 3.47% lower at $57.65. The Company's shares have advanced 132.74% over the previous three months and 369.85% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 32.71% and 119.32%, respectively. Furthermore, shares of Nektar Therapeutics, which develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the US, have an RSI of 64.88. Sign up today for the free research report on NKTR at:
Philadelphia, Pennsylvania headquartered Spark Therapeutics Inc.'s stock finished Tuesday's session 3.68% higher at $53.31 with a total trading volume of 630,682 shares. The Company's shares have advanced 5.40% in the past twelve months. The stock is trading below its 50-day moving average by 22.07%. Additionally, shares of Spark Therapeutics, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases, have an RSI of 40.70.
On December 14th, 2017, research firm Goldman downgraded the Company's stock rating from 'Buy' to 'Neutral' while revising its previous target price from $106 a share to $58 a share. Wall St. Equities' research coverage also includes the downloadable free report on ONCE at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----grifols-advaxis-nektar-therapeutics-and-spark-therapeutics-300576885.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Blood groups are of four important groups determined by the presence or absence of specific ...
Spermatocele is a condition in which there is a blockage in the epididymal duct, resulting in semen ...
Be a blood donor and save lives for your donated blood is separated into blood products or just ...View All